Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Bonus Article from MarketBeat.com Moderna Pops 17%—Is There Life in MRNA, Down 90% from COVID High?Author: Leo Miller. Publication Date: 1/20/2026. 
At a Glance - Moderna was one of the top vaccine providers during the pandemic, generating +$7 billion in sales one quarter.
- Shares are now down more than 90% from their high, following the path of COVID-19 vaccine sales.
- However, Moderna just posted its biggest gain in over three years after updating its guidance. Does the stock have real rebound potential?
In a blast from the past, COVID-19 vaccine developer Moderna (NASDAQ: MRNA) made headlines again in 2026. Shares jumped more than 17% on Jan. 13, the company's largest single-day gain in over three years. Moderna shares have fallen sharply as COVID-19's relevance has waned. Trading near $42 per share as of Jan. 20, the stock is down over 90% from its all-time high—even after the recent bounce. If you missed out on gold's recent run…You've been given a second chance.
Because the gold market is moving to the next phase.
Something we call the Golden Paradox.
It's a hidden opportunity that's played out for nearly 100 years.
A way that could've helped investors make 31 times more …65 times more … Even 469 times more than just buying gold. To solve this Golden Paradox, click here With the stock in such a deep hole and the pharma company recently raising its outlook, can Moderna shares rebound? MRNA Expects Stability in 2026 After COVID Sales Plummet The spike in Moderna stock followed the company's announcement of better-than-expected revenue guidance and stronger-than-expected cost controls. For 2025, Moderna said it expects to generate $1.9 billion in revenue—$100 million above its previously outlined midpoint. The company also forecasted operating expenses roughly $200 million below prior estimates. It expects non-adjusted operating expenses for 2025 to be between $5.0 billion and $5.2 billion, about $2 billion lower than the prior year. On a cash basis, Moderna projects costs between $3.5 billion and $3.9 billion by 2027. Almost all of Moderna's sales still come from COVID-19 vaccines. Of the firm's $1 billion in revenue last quarter, $971 million came from COVID vaccines—weak compared with late 2021, when the company generated $7.2 billion in one quarter. As of the end of 2023, the World Health Organization estimated that 67% of the world's population had received the complete primary series of a COVID-19 vaccine. That leaves a much smaller pool of potential patients for Moderna to generate sales from, making it difficult to see sustainable growth based solely on its COVID treatments. Still, Moderna expects up to 10% sales growth in 2026, driven by repeatable COVID-19 booster sales to high-risk individuals and seniors. The company has strategic partnerships with the governments of Canada, the United Kingdom and Australia, and 2026 will be the first full year to show the benefit of those deals. Notably, in Q1 2026 the firm expects $200 million in sales from the U.K. government. Targeting high-risk populations and securing government contracts could help establish a stable revenue base. MRNA Seeks 2028 Break-Even, Needs Positive Non-Seasonal Readouts Moderna believes a seasonal vaccine strategy combined with cost reductions can achieve breakeven cash flow by 2028. The company recently released Phase 3 results for a flu vaccine; the treatment could be approved in 2026 and begin generating meaningful revenue in 2027. That would be a major catalyst, adding a second seasonal product aimed at a widespread infection. Approval is essential if the firm is to have a realistic shot at its 2028 target. However, to rekindle strong investor enthusiasm, Moderna will likely need successes beyond seasonal vaccines. Seasonal markets provide a revenue floor but limited long-term growth. To sustain growth, the company will need progress in its oncology and rare disease pipelines. Moderna has several candidates in these areas with pivotal readouts expected in 2026. The most important is its personalized cancer medicine, intismeran: the company expects five-year Phase Two data in early 2026, with Phase Three data possible in late 2026. Despite Recent Excitement, Moderna Remains a Wait-and-See Stock Overall, uncertainty still clouds Moderna's outlook. Whether the company's COVID-19 vaccine sales have truly bottomed is far from certain. Long-term prospects depend heavily on approvals in clinical areas where Moderna currently has no marketed drugs. The Trump administration has also been critical of mRNA technology, winding down government investments in the area in which Moderna specializes—a development that has raised concerns about future support for mRNA programs. For now, Moderna is a stock to watch. The consensus price target, near $30, implies more than 25% downside from current levels. Seeing stabilization in COVID-19 vaccine demand—or clear clinical progress outside of seasonal vaccines—would be key prerequisites for a more bullish view on the stock's long-term prospects.
| 
